Results 41 to 50 of about 3,249 (159)

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities

open access: yesVaccines, 2017
Nucleolin (NCL) has been reported as a cellular receptor for the human respiratory syncytial virus (RSV). We studied the effects of re-purposing AS1411, an anti-cancer compound that binds cell surface NCL, as a possible novel strategy for RSV therapy in ...
Peter Mastrangelo   +5 more
doaj   +1 more source

Nucleolin recognizing silica nanoparticles inhibit cell proliferation by activating the Bax/Bcl-2/caspase-3 signalling pathway to induce apoptosis in liver cancer

open access: yesFrontiers in Pharmacology, 2023
Multifunctional nanocarrier platforms have shown great potential for the diagnosis and treatment of liver cancer. Here, a novel nucleolin-responsive nanoparticle platform was constructed for the concurrent detection of nucleolin and treatment of liver ...
Liangliang Xiang   +6 more
doaj   +1 more source

Development and Evaluation of AT11-Guided Liposomes for Human Papillomavirus Cancer

open access: yesMedical Sciences Forum, 2022
Conventional anticancer therapies present low specificity, leading to several secondary effects. To improve these drawbacks, aptamers able to fold into G-quadruplex (G4) are being used to promote drug accumulation in cancer cells.
Jéssica Lopes-Nunes   +2 more
doaj   +1 more source

Migration and invasion inhibition induced by AS1411.

open access: yes, 2016
(a) AS1411 inhibited the migration of glioma cells in vitro. The migration capabilities of U87, U251, SHG44 and NHA cells were assessed after pretreatment with AS1411 of 0 to 10 μM and CRO of 10μM. Akt1 overexpression antagonized AS1411 induced migration
Gang Zhao (161405)   +8 more
core   +1 more source

Anti-tumor effects of modified AS1411-aptamers on SNU-761 cells.

open access: yes, 2016
(A) Significant cytotoxic effects on SNU-761 cells were noted with modified AS1411-aptamer treatment under both normoxic and hypoxic conditions. (B) Cell cycle analysis revealed that modified AS1411-aptamer significantly decreased the proportion of S ...
Su Jong Yu (313985)   +11 more
core   +1 more source

A New Paradigm for Aptamer Therapeutic AS1411 Action: Uptake by Macropinocytosis and Its Stimulation by a Nucleolin-Dependent Mechanism

open access: yes, 2010
AS1411 is a first-in-class anticancer agent, currently in phase II clinical trials. It is a quadruplex-forming oligodeoxynucleotide that binds to nucleolin as an aptamer, but its mechanism of action is not completely understood.
E. Merit Reyes-Reyes   +2 more
core   +1 more source

Aptamer-Functionalized Iron-Based Metal–Organic Frameworks (MOFs) for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy

open access: yesMolecules, 2022
Hypoxia-activated prodrugs (HAPs) with selective toxicity in tumor hypoxic microenvironments are a new strategy for tumor treatment with fewer side effects.
Xuan Wang, Qing Chen, Congxiao Lu
doaj   +1 more source

Aptamer-programmable adeno-associated viral vectors as a novel platform for cell-specific gene transfer

open access: yesMolecular Therapy: Nucleic Acids, 2023
Adeno-associated viruses (AAVs) are commonly used for in vivo gene therapy. Nevertheless, the wide tropism that characterizes these vectors limits specific targeting to a particular cell type or tissue.
Francesco Puzzo   +5 more
doaj   +1 more source

Intracellular staining of free Dox and AS1411-Dox with Control DNA-Dox adduct.

open access: yes, 2015
(a) Confocal laser scanning microscopy images displaying uptake of Dox into Huh7 cells treated with 2 μM of free Dox, AS1411-Dox adduct, or control DNA-Dox adduct, respectively.
Chen Liu (75209)   +7 more
core   +1 more source

AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation

open access: yes, 2021
Proliferative retinopathies produces an irreversible type of blindness affecting working age and pediatric population of industrialized countries. Despite the good results of anti-VEGF therapy, intraocular and systemic complications are often associated ...
Beatriz Buentello-Volante   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy